Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathwaysVincenzo Quagliariello, Nicola Maurea, Maria Laura Canale et al.|Frontiers in Cardiovascular Medicine|2022Cited by 48
Corrigendum: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathwaysVincenzo Quagliariello, Nicola Maurea, Margherita Passariello et al.|Frontiers in Cardiovascular Medicine|2023Cited by 6
Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, Galectine-3 and NLRP3-MyD88-chemokine pathways.Vincenzo Quagliariello, Nicola Maurea, Margherita Passariello et al.|Journal of Clinical Oncology|2022Cited by 2
Pembrolizumab, Ipilimumab and Nivolumab reduces cardiac pAMPK and IL-10, increases vascular NF-kB expression and levels of IL-1b, IL-2 and IL-6 in myocardial tissueNicola Maurea, Vincenzo Quagliariello, C De Lorenzo et al.|European Heart Journal|2022Cited by 1
CTLA-4 and PD-1 blocking agents affects longitudinal and radial strain in preclinical models, increases systemic SDF-1, cardiac fibronectin, S-100 calgranulin, galectine-3 and NLRP-3/MyD-88 pathwaysNicola Maurea, Vincenzo Quagliariello, Claudia De Lorenzo et al.|European Heart Journal - Cardiovascular Imaging|2023Cited by 1